Pseudomonas aeruginosa: Recent Advances in Vaccine Development

Killough, Matthew; Rodgers, Aoife M.; Ingram, Rebecca J.

doi:10.3390/vaccines10071100

Cited by 42 publications

(31 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite these considerable efforts, no vaccine has yet been found to be clinically efficacious against this pathogen. The main obstacles to achieve this goal include poor immunogenicity of the protective epitopes, a large variant subtype antigens, leading to high degree of serologic variability, a large genome facilitating adaptation to new environments, phenotypic plasticity between acute and chronic infection, and variations in animal responses to P. aeruginosa that make determination of the optimal vaccine formulations difficult from such studies [400,413]. 7.5.…”

Section: Vaccine Development Against P Aeruginosamentioning

confidence: 99%

Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics

Wood

Kuzel

Shafikhani

2023

Cells

View full text Add to dashboard Cite

Pseudomonas aeruginosa is an important Gram-negative opportunistic pathogen which causes many severe acute and chronic infections with high morbidity, and mortality rates as high as 40%. What makes P. aeruginosa a particularly challenging pathogen is its high intrinsic and acquired resistance to many of the available antibiotics. In this review, we review the important acute and chronic infections caused by this pathogen. We next discuss various animal models which have been developed to evaluate P. aeruginosa pathogenesis and assess therapeutics against this pathogen. Next, we review current treatments (antibiotics and vaccines) and provide an overview of their efficacies and their limitations. Finally, we highlight exciting literature on novel antibiotic-free strategies to control P. aeruginosa infections.

show abstract

Section: Vaccine Development Against P Aeruginosamentioning

confidence: 99%

Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics

Wood

Kuzel

Shafikhani

2023

Cells

View full text Add to dashboard Cite

show abstract

“…Pseudomonas aeruginosa is a conditionally pathogenic bacterium widely present in nature, human skin, intestine, and respiratory tract; studies have shown that P. aeruginosa is an important causative agent of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) (Pang et al, 2019); notably, P. aeruginosa is prone to cause intranasal and ventilator-associated pneumonia in immunocompromised and hospitalized patients (Killough et al, 2022). Consistent with this, we found that P. aeruginosa abundance in BALF was negatively correlated with whole blood WBC counts and CD4 + T cell counts; also, in this study, we found that the number of bacterial species detected in BALF was elevated in the immunodeficient group relative to the non-immunodeficient group (Supplementary Figure 7A).…”

Section: Correlation Of Abundance Of Potentially Pathogenic Bacteria ...mentioning

confidence: 99%

Metagenomic next-generation sequencing of bronchoalveolar lavage fluid from children with severe pneumonia in pediatric intensive care unit

Zhang

Liu

Wang

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundSevere pneumonia due to lower respiratory tract infections (LRTIs) is a significant cause of morbidity and mortality in children. Noninfectious respiratory syndromes resembling LRTIs can complicate the diagnosis and may also make targeted therapy difficult because of the difficulty of identifying LRTI pathogens. In the present study, a highly sensitive metagenomic next-generation sequencing (mNGS) approach was used to characterize the microbiome of bronchoalveolar lavage fluid (BALF) in children with severe lower pneumonia and identify pathogenic microorganisms that may cause severe pneumonia. The purpose of this study was to use mNGS to explore the potential microbiomes of children with severe pneumonia in a PICU.MethodsWe enrolled patients meeting diagnostic criteria for severe pneumonia admitted at PICU of the Children’s Hospital of Fudan University, China, from February 2018 to February 2020. In total, 126 BALF samples were collected, and mNGS was performed at the DNA and/or RNA level. The pathogenic microorganisms in BALF were identified and correlated with serological inflammatory indicators, lymphocyte subtypes, and clinical symptoms.ResultsmNGS of BALF identified potentially pathogenic bacteria in children with severe pneumonia in the PICU. An increased BALF bacterial diversity index was positively correlated with serum inflammatory indicators and lymphocyte subtypes. Children with severe pneumonia in the PICU had the potential for coinfection with viruses including Epstein–Barr virus, Cytomegalovirus, and Human betaherpesvirus 6B, the abundance of which was positively correlated with immunodeficiency and pneumonia severity, suggesting that the virus may be reactivated in children in the PICU. There was also the potential for coinfection with fungal pathogens including Pneumocystis jirovecii and Aspergillus fumigatus in children with severe pneumonia in the PICU, and an increase in potentially pathogenic eukaryotic diversity in BALF was positively associated with the occurrence of death and sepsis.ConclusionsmNGS can be used for clinical microbiological testing of BALF samples from children in the PICU. Bacterial combined with viral or fungal infections may be present in the BALF of patients with severe pneumonia in the PICU. Viral or fungal infections are associated with greater disease severity and death.

show abstract

“…Interestingly, although the use of LPS in vaccines can have considerable side effects, in this study, the administration of EVs without modification or removal of LPS did not seem to generate unwanted effects [ 82 ]. Most studies using well-characterized Pseudomonas antigens for vaccine development in the last 50 years have been unsuccessful [ 83 ]. Only a small number of them have entered clinical trials.…”

Section: Extracellular Vesicles As Biotechnological Toolsmentioning

confidence: 99%

Extracellular Vesicles of Pseudomonas: Friends and Foes

Henríquez

Falciani

2023

Antibiotics

View full text Add to dashboard Cite

Extracellular vesicles (Evs) are small spherical vesicles capable of transporting molecules (such as proteins, nucleic acids and lipids) from one cell to another. They have been implicated in processes such as cell-to-cell communication, pathogenicity, biofilm formation and metabolism. In parallel, Evs have been proposed as interesting biotechnological tools. In recent years, antibiotic resistance has become a major problem for human health worldwide. A pathogen singled out as among the most lethal antibiotic-resistant organisms is Pseudomonas aeruginosa, an important Gram-negative bacterium that has been extensively studied for the production and characterization of Evs. Here, we describe the advances made in the last decade regarding understanding of the role of Evs in the pathogenicity of Pseudomonas. We also examine the potential of Evs for the development of new treatment strategies.

show abstract

Pseudomonas aeruginosa: Recent Advances in Vaccine Development

Cited by 42 publications

References 121 publications

Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics

Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics

Metagenomic next-generation sequencing of bronchoalveolar lavage fluid from children with severe pneumonia in pediatric intensive care unit

Extracellular Vesicles of Pseudomonas: Friends and Foes

Contact Info

Product

Resources

About